ABBV · News · 20260910N
Licensing / Collaboration Deals
AbbVie Inc. · 2026-09-10 · Importance 58 · Surprise 42 · In source text
AbbVie’s collaboration with ADARx Pharmaceuticals is supporting development of RNA-targeted therapies for hepatic and non-hepatic diseases. The agreement provided ADARx with $335 million in upfront cash and $385 million in option payments, with potential milestones of up to $7.45 billion plus royalties. ADARx’s lead candidate, Onvuzosiran, is in Phase 3 development for hereditary angioedema, with topline data expected by the end of 2027 and a potential NDA in 2028.
Key facts
- A collaboration deal between ADARx Pharmaceuticals and AbbVie provided $335 million in upfront cash, $385 million in option payments, and up to $7.45 billion in milestones, plus royalties. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| liability | negative | contingent | -0.8% | A collaboration deal between ADARx Pharmaceuticals and AbbVie provided $335 million in upfront cash, $385 million in option payments, and… |
| liability | negative | committed | -0.2% | A collaboration deal between ADARx Pharmaceuticals and AbbVie provided $335 million in upfront cash, $385 million in option payments, and… |
| cash | negative | committed | -0.2% | A collaboration deal between ADARx Pharmaceuticals and AbbVie provided $335 million in upfront cash, $385 million in option payments, and… |
| operating_income | negative | contingent | — | A collaboration deal between ADARx Pharmaceuticals and AbbVie provided $335 million in upfront cash, $385 million in option payments, and… |